drugset
drugset / Trial / NCT02710188

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

NCT02710188 ↗

Phase 1 Completed 14 enrolled Nxera Pharma UK Limited Quotient Clinical · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.

Timeline

Start
2016-02
Primary completion
2016-07
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HTL-9936 Small molecule — Oral

Indications

Alzheimer disease